YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines

World Journal of Gastroenterology

Volumn 11, Issue 6, 2005, Pages 867-870

  Huang, Zhong Min ^a   Huang, Qi Wen ^a   Qin, Ya Qin ^a   He, Yan Zhuan ^a   Qin, Hou Ji ^a   Zhou, Yiao Nan ^a   Xu, Xiang ^a   Huang, Mei Jin ^a  

^a Affiliated Hospital of Medical College of You Jiang for Nationality   (China)

Author keywords

Chronic hepatitis; Genotypes; Hepatitis B virus; Lamivudine; YMDD mutation

Indexed keywords

BIOLOGICAL MARKER; LAMIVUDINE; NUCLEIC ACID; POLYMERASE P; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANALYSIS; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; VIRUS GENE;

EID: 14544270973     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i6.867     Document Type: Article

References (34)

1. Schemes of prevention and cure for viral hepatitis in hepatology branch-conference of Infectious Diseases and Parasitic Disease Association of Chinese Medical Association. Zhonghua Ganzangbing Zazhi 2000; 8: 324-329
2. Wang H, Wan CS, Wang SL, Peng HG. Study on genotypes of HBV DNA using PCR microplate hybridization-ELISA. Zhonghua Weishengwuxue He Mianyixue Zazhi 2001; 21: 234-236
3. Xu D, Tian DY, Wang WH, Chen HY, Xing MY, Guo W, Song PH. Emergence and clinical significance of YMDD and HBeAg-related mutations during lamivudine treatment. Zhonghua Neike Zazhi 2004; 43: 121-124
4. Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol 2004; 73: 7-12
5. Liaw YF. Results of lamivudine trials in asia. J Hepatol 2003; 39(Suppl 1): S111-115
6. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. The long-term efficacy of lamivudine on chronic hepatitis B: Interim analysis of 3-year's clinical course. Zhonghua Neike Zazhi 2003; 42: 382-387
7. Song JW, Lin JS, Kong XJ, Liang KH. Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus. Zhonghua Ganzangbing Zazhi 2003; 11: 361-363
8. Liu Z. Individual therapy for the patients with YMDD mutation in HBV by lamivudine. Zhonghua Ganzangbing Zazhi 2003; 11: 558
9. Hu YY, Jiang JJ, Li D, Lin CW, Li QG, Chen Y. Evaluation of different methods in monitoring YMDD motif mutations associated with lamivudine resistance. Zhonghua Ganzangbing Zazhi 2003; 11: 427-430
10. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22
11. Yao G, Wang B, Cui Z, Zheng M. Long-term effect of lamivudine treatment in chronic hepatitis B virus infection. Zhonghua Ganzangbing Zazhi 1999; 7: 80-83
12. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem Pharmacol 1998; 55: 1567-1572
13. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R. Genotypic and phenotypic resistance: Longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patient with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003; 98: 151-159
14. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med 2003; 253: 544-552
15. Wang JH, LU SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002; 37: 366-369
16. Ogata N, Ichida T, Aoyagi Y, Kitajima I. Development of peptide ncleic acid mediated polymerase chain reaction lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity. Rinsho Byori 2003; 51: 313-319
17. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63
18. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, Toyama T, Minami M. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment, J Hepatol 2002; 37: 259-265
19. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584-586
20. Yan MH, Zhang C, Ling Q, Zhou RF. Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2003; 11: 430-431
21. Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, Legendre C, Kreis H, Pol S. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 2090-2094
22. Zhang XH, Zhang YX, Sun LR, Wen Q, Zhou LQ, Fan GX, Zhang X, Yang DG. Study of gene chips in the detection of YMDD mutations in the region of HBV polymeras. Zhonghua Yixue Zazhi 2003; 83 459-462
23. Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Takagi K, Kobayashi M, Ikeda K, Kumada H. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004; 39: 34-40
24. Ye XG, Wang RL, Guo HB. Detection and analysis of YMDD mutate genes in patients of chronic hepatitis B before being treated. Zhonghua Jianyan Yixue Zazhi 2002; 25: 248
25. Da Silva LC, da Fonseca LE, Carrilho FJ, Alves VA, Sitnik R, Pinho JR. Predictive factors for response to lamivudine in chronic hepatitis B. Rev Inst Med Trop Sao Paulo 2000; 42: 189-196
26. Kobayashi S. Clinical characteristics of asymptomatic hepatitis B virus carriers with YMDD mutant not treated with lamivudine. Kurume Med J 2003; 50: 87-90
27. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group. Hepatology 1999; 29: 889-896
28. Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol 2002; 17(Suppl): S125-145
29. Alberti A, Brunetto MR, Colombo M, Craxi A. Recent progress and new trends in the treatment of hepatitis B. J Med Virol 2002; 67: 458-462
30. Wu GX, Zha YS, Zheng J, Wang YZ, Zhou GP. Effect of interferon combined with lamivudine in treatment of chronic hepatitis B patients infected with HBV with mutation of YMDD. Zhonghua Ganzangbing Zazhi 2003; 11: 752-753
31. Zhou F, Wang LT, Chen JJ. Therapeutic efficacy of combined application of lamivudine and bushen recipe in treating chronic hepatitis B and its influence on YMDD motif. Zhongguo Zhongxiyi Jiehe Zazhi 2003; 23: 417-420
32. Deng H, Zhao ZX, Xu QH, Zhou YP, Chen YM, Yao JL. Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi 2003; 11: 305-308
33. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000; 46: 562-568
34. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126 81-90